Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seralutinib - Gossamer Bio

Next Previous
Drug Profile

Seralutinib - Gossamer Bio

Alternative Names: GB-002; PK-10571

Latest Information Update: 11 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator YM BioSciences
  • Developer Gossamer Bio
  • Class Amides; Pyrazines; Pyridines; Small molecules
  • Mechanism of Action Macrophage colony-stimulating factor receptor antagonists; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pulmonary arterial hypertension; Pulmonary hypertension

Most Recent Events

  • 05 Nov 2025 Phase-III clinical trials in Pulmonary hypertension (Treatment-experienced) in USA (Inhalation) (NCT07181382) (CTIS2025-521777-13-00)
  • 16 Jun 2025 Gossamer Bio completes enrolment in the phase III PROSERA trial in Pulmonary arterial hypertension (Treatment-experienced) in the US, Argentina, Australia, Austria, Belgium, Brazil, Chile, Czech Republic, Canada, Denmark, France, Germany, Greece, Israel, Italy, Japan, Latvia, Lithuania, Mexico, the Netherlands, Poland, Portugal, Puerto Rico, Romania, Serbia, Singapore, South Korea, Spain and the UK (Inhalation) (NCT05934526; EudraCT2023-503614-80-00)
  • 17 May 2025 Pharmacodynamics data from preclinical trials for Pulmonary arterial hypertension presented at the 121st International Conference of the American Thoracic Society (ATS-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top